ONCE-DAILY ATOMOXETINE FOR ADHD: UPDATE ON EVENING AND MORNING BEHAVIOR

Objectives: To assess the duration of atomoxetine (ATX), dosed once daily in the morning (AM) or evening (PM), on core ADHD symptoms and behaviors during the PM and early AM. Methods: In Trial 1, 197 patients received AM ATX or placebo (PBO). In Trial 2, 288 patients received AM ATX/PM PBO, AM PBO/PM ATX, or 2 PBO doses. Results: In Trial 1, ATX was more effective than PBO on the ADHD Rating Scale (ADHD RS), Conners' Global Index Parent-Evening (CGIP-E) Total score, and the Daily Parent Rating of Evening and Morning Behavior-Revised (DPREMB-R) Evening subscore. The DPREMB-R Morning subscore showed symptom reduction into the next AM. In Trial 2, AM and PM ATX were superior to PBO on the ADHD RS Total score. AM ATX was superior to PM ATX on the ADHD RS Total score and Hyperactive/Impulsive subscore. Significant efficacy up to 18 hours later was shown for AM ATX on the DPREMB-R Evening subscore, CGIP-E Total score, and CGIP-E Restless-Impulsive subscore, and for PM ATX on the CGIP-M Total score and CGIP-M Restless-Impulsive subscore. Significant efficacy up to 24 hours later was shown for AM ATX on the CGIP-M Total score, and for PM ATX on the CGIP-E Total score, CGIP-E Restless-Impulsive subscore, and DPREMB-R Evening subscore. Conclusion: AM or PM ATX decreased core ADHD symptoms relative to PBO and reduced symptoms up to 24 hours later. AM ATX had greater efficacy and PM ATX had greater tolerability.